RCT | Second-line treatment with Axi-cel results in increased overall survival in large B-cell lymphoma

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma – University of Texas MD Anderson Cancer Center

Commentary: Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma – The ASCO Post

Commentary on Twitter

Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:

— NEJM (@NEJM) June 5, 2023